The absence of licensed vaccines for several high-fatality pathogens shows how market-driven pharmaceutical R&D fails. Discuss with reference to the 2026 Bundibugyo Ebola outbreak.

The 2026 Bundibugyo outbreak in the DRC and Uganda was declared a PHEIC on 17 May 2026 [4]. By 23 September it had recorded 7,890 confirmed cases and 3,799 deaths (CFR 48.1%) [3]. Yet there is still no licensed vaccine or specific treatment for Bundibugyo virus disease [2]. Market failure explains most of this gap, but limits of science and preparedness also play a part.

How market logic left Bundibugyo behind

• Thin, unpredictable demand: the DRC has had only two Bundibugyo outbreaks, in 2012 and 2026 [3]. Without regular buyers, there is no assured return on investment.
• Species-specific science raises costs: Ervebo, the only licensed Ebola vaccine, covers only the Zaire species [2]. Each species therefore needs its own development programme, each with little revenue.
• Low purchasing power: the burden falls on conflict-hit Ituri and North Kivu [3]. These areas cannot create profitable demand.
• Public "push" funding fills the gap: IAVI received $36 million of a U.S. contract worth up to $99 million for a single-dose candidate only after cases crossed 10,000 [1]. WHO's R&D Blueprint (2016) was set up precisely for diseases that lack countermeasures [9].

Beyond market failure

• Science moves slower than outbreaks: the Oxford–Serum Institute of India candidate had only reached Phase 1 by July 2026 [8]. In Uganda's 2022 Sudan-virus outbreak, candidate vaccines arrived in a record 79 days [6]. The outbreak still ended (164 cases, 77 deaths) before their efficacy could be proven [7].
• Ethics of evidence: Ervebo cannot be used at scale while its effect on Bundibugyo is unproven. So 20,000 ICG doses go to a Phase 3 trial and 50,000 to frontline workers [5].
• Thin emergency finance: WHO first released only US$3.9 million from its Contingency Fund for Emergencies [10].

Way forward

• Prepare approved trial protocols and candidate doses before outbreaks begin.
• Set up an ICG Bundibugyo stockpile once a vaccine is proven.
• Add pull incentives such as advance purchase commitments, using India's low-cost manufacturing scale [8].

The Bundibugyo gap shows that markets alone will not build vaccines for rare, deadly diseases of the poor. Public funding, science and preparedness decide how quickly that gap closes. Push funding combined with standing trial readiness, stockpiles and pull incentives, as the R&D Blueprint envisions [9], can make such vaccines a global public good and advance SDG 3.